Evommune vs Tonix Pharmaceuticals
Tonix Pharmaceuticals reported revenue of $13 million in fiscal 2025, about the same as Evommune's $13 million in fiscal 2025. Evommune's revenue grew 85.7% in its latest year, and Tonix Pharmaceuticals' grew 29.9%. Evommune had an operating margin of -623.6%, against -959.0% at Tonix Pharmaceuticals. Free cash flow was −$77 million at Evommune and −$103 million at Tonix Pharmaceuticals.
Side by side
| Evommune | Tonix Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $13M | $13M |
| Revenue growth | 85.7% | 29.9% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | 49.3% |
| Operating margin | −623.6% | −959.0% |
| Net margin | −529.8% | −946.2% |
| Free cash flow | −$77M | −$103M |
| Free cash flow margin | −589.8% | −787.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $14M |
| Change in diluted share count | 306.9% | 1,055.9% |
| Last close | $7.24 | $2.55 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $163,610, sold $2.3 million | bought $458,758, sold $0 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
EvommuneTonix Pharmaceuticals
Operating margin
Percent of revenue
EvommuneTonix Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
EvommuneTonix Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Evommune and Tonix Pharmaceuticals pages.